Sign in
Taking peopleNo phase

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Key facts

Who runs it
Artcline GmbH
Where
Germany2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
142 people, planned
Started
1 Jan 2024
Expected to end
28 Feb 2030
Type of study
Observational, 2 groups
Record updated
2 August 2024

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent
  • Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial

Who cannot take part

  • none

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in Germany.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.

Read full original descriptionShow less

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

The 2 groups in the trial

  • Control group

    Subjects in this group where randomized in the control group in the ReActiF-ICE study previously

  • Therapy Group

    Subjects in this group where randomized in the therapy group in the ReActiF-ICE study previously

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06143137, who can take part
Record updated
2 August 2024